Clinical Study Shows Targeted End-tidal Control Anesthesia Delivery Improves Efficiency and Accuracy to Help Optimize Patient Care
GE HealthCare (Nasdaq: GEHC) announced the publication of the MASTER trial results in Anesthesia and Analgesia, demonstrating the safety and efficacy of End-tidal Control software for inhaled anesthetic administration. The study, conducted across four U.S. hospitals with 210 adult patients, showed that End-tidal Control achieved:
- Targeted end-tidal anesthetic concentrations within 5% of the set value 98% of the time, compared to 46% with manual control
- Targeted end-tidal oxygen concentrations within 5% of the set value 86% of the time, versus 41% with manual control
- Faster response times for achieving 90% of the initial desired end-tidal anesthetic concentration (median 75 seconds vs. 158 seconds)
The software also demonstrated potential to reduce anesthetic agent usage, greenhouse gas emissions, and costs compared to manual control.
GE HealthCare (Nasdaq: GEHC) ha annunciato la pubblicazione dei risultati del trial MASTER su Anesthesia and Analgesia, che dimostra la sicurezza e l'efficacia del software End-tidal Control per la somministrazione di anestetici inalatori. Lo studio, condotto in quattro ospedali degli Stati Uniti su 210 pazienti adulti, ha mostrato che End-tidal Control ha raggiunto:
- Concentrazioni anestetiche target alla fine dell'espirazione entro il 5% del valore impostato nel 98% dei casi, rispetto al 46% con il controllo manuale
- Concentrazioni di ossigeno target alla fine dell'espirazione entro il 5% del valore impostato nell'86% dei casi, rispetto al 41% con il controllo manuale
- Tempi di risposta più rapidi per raggiungere il 90% della concentrazione anestetica desiderata alla fine dell'espirazione (mediana di 75 secondi contro 158 secondi)
Il software ha inoltre dimostrato il potenziale di ridurre l'uso di agenti anestetici, le emissioni di gas serra e i costi rispetto al controllo manuale.
GE HealthCare (Nasdaq: GEHC) anunció la publicación de los resultados del ensayo MASTER en Anesthesia and Analgesia, que demuestra la seguridad y eficacia del software End-tidal Control para la administración de anestésicos inhalados. El estudio, realizado en cuatro hospitales de EE. UU. con 210 pacientes adultos, mostró que End-tidal Control logró:
- Concentraciones anestésicas finales objetivo dentro del 5% del valor establecido el 98% del tiempo, en comparación con el 46% con control manual
- Concentraciones de oxígeno finales objetivo dentro del 5% del valor establecido el 86% del tiempo, frente al 41% con control manual
- Tiempos de respuesta más rápidos para alcanzar el 90% de la concentración anestésica deseada al final de la espiración (mediana de 75 segundos frente a 158 segundos)
El software también demostró potencial para reducir el uso de agentes anestésicos, las emisiones de gases de efecto invernadero y los costos en comparación con el control manual.
GE 헬스케어(Nasdaq: GEHC)는 흡입 마취제 투여를 위한 End-tidal Control 소프트웨어의 안전성과 효능을 입증한 MASTER 시험 결과를 Anesthesia and Analgesia에 발표했습니다. 이 연구는 210명의 성인 환자를 대상으로 미국의 4개 병원에서 진행되었으며, End-tidal Control은 다음을 달성했습니다:
- 설정된 값의 5% 이내의 목표 호흡 끝 마취 농도를 98%의 시간 동안 달성하였으며, 수동 조작에서는 46%에 불과했습니다.
- 설정된 값의 5% 이내의 목표 호흡 끝 산소 농도를 86%의 시간 동안 달성하였으며, 수동 조작에서는 41%에 불과했습니다.
- 초기 원하는 호흡 끝 마취 농도의 90%에 도달하는 데 걸리는 시간(중앙값 75초 vs. 158초)이 더 짧았습니다.
이 소프트웨어는 또한 수동 조작에 비해 마취제 사용, 온실가스 배출 및 비용을 줄이는 잠재력을 입증했습니다.
GE HealthCare (Nasdaq: GEHC) a annoncé la publication des résultats de l'
- Des concentrations anesthésiques finales ciblées à moins de 5% de la valeur définie 98% du temps, contre 46% avec le contrôle manuel
- Des concentrations d'oxygène finales ciblées à moins de 5% de la valeur définie 86% du temps, contre 41% avec le contrôle manuel
- Des temps de réponse plus rapides pour atteindre 90% de la concentration anesthésique finale souhaitée (médiane de 75 secondes contre 158 secondes)
Le logiciel a également démontré un potentiel pour réduire l'utilisation d'agents anesthésiques, les émissions de gaz à effet de serre et les coûts par rapport au contrôle manuel.
GE HealthCare (Nasdaq: GEHC) gab die Veröffentlichung der Ergebnisse der MASTER-Studie in Anesthesia and Analgesia bekannt, die die Sicherheit und Wirksamkeit der End-tidal Control-Software für die Verabreichung von inhalativen Anästhetika belegt. Die Studie, die an vier US-Krankenhäusern mit 210 erwachsenen Patienten durchgeführt wurde, zeigte, dass End-tidal Control folgende Ergebnisse erzielte:
- Gezielte end-tidal Anästhetik-Konzentrationen innerhalb von 5% des festgelegten Wertes in 98% der Fälle, im Vergleich zu 46% mit manueller Steuerung
- Gezielte end-tidal Sauerstoffkonzentrationen innerhalb von 5% des festgelegten Wertes in 86% der Fälle, im Vergleich zu 41% mit manueller Steuerung
- Schnellere Reaktionszeiten, um 90% der anfänglich gewünschten end-tidal Anästhetik-Konzentration zu erreichen (Median 75 Sekunden vs. 158 Sekunden)
Die Software zeigte auch Potenzial zur Reduzierung des Einsatzes von Anästhetika, der Treibhausgasemissionen und der Kosten im Vergleich zur manuellen Steuerung.
- End-tidal Control software achieved and maintained targeted anesthetic and oxygen concentrations more accurately than manual control
- The software reduced response times for achieving desired anesthetic concentrations by over 50%
- End-tidal Control demonstrated potential to reduce anesthetic agent usage, greenhouse gas emissions, and costs
- A separate study showed a potential 44% decline in greenhouse emissions when using End-tidal Control software
- The American Medical Association approved a new Category III CPT code to track patient outcomes associated with End-tidal Control software use
- None.
The MASTER trial results present compelling evidence for the efficacy of End-tidal Control software in anesthesia delivery. The study, involving 210 adult patients across four U.S. hospitals, demonstrated significant improvements in achieving and maintaining targeted anesthetic and oxygen concentrations. End-tidal Control achieved target concentrations within 5% of the set value
Moreover, the software showed faster response times, reaching 90% of the desired anesthetic concentration in a median of 75 seconds, compared to 158 seconds for manual control. This efficiency could be particularly beneficial in dynamic surgical environments where rapid adjustments are often necessary. The potential
The introduction of End-tidal Control software presents a significant opportunity for GE HealthCare (GEHC) in the anesthesia delivery market. The software's ability to reduce anesthetic agent usage by over
Furthermore, the recent approval of a Category III CPT code by the American Medical Association for tracking patient outcomes associated with End-tidal Control could accelerate its integration into clinical practice. This could lead to increased revenue streams for GEHC if the software demonstrates improved patient outcomes and cost-effectiveness in real-world settings. Investors should monitor GEHC's market penetration and revenue growth in the anesthesia delivery segment, as this innovation could become a key differentiator in a competitive medical device landscape.
The End-tidal Control software represents a significant advancement in anesthesia automation. By leveraging algorithms to maintain precise anesthetic and oxygen concentrations, it addresses the challenges of manual adjustments in low-flow anesthesia. This automation not only enhances accuracy but also reduces the cognitive load on anesthesiologists, allowing them to focus on other critical aspects of patient care.
The software's ability to achieve target concentrations more consistently and quickly than manual control (
- Published in Anesthesia and Analgesia, results from the multi-site trial evaluating End-tidal Control software provide compelling evidence for enhanced accuracy and efficiency of anesthesia delivery compared to conventional anesthetic gas delivery methods.1
- End-tidal Control is the first FDA-approved software that automatically adjusts and maintains exhaled oxygen and exhaled anesthetic concentrations, with more accuracy in reaching the clinician’s target versus manual control. The utilization of End-tidal Control software reduces manual adjustments by clinicians, enabling them to focus on time with their patients.2
- Results support End-tidal Control’s ability to reduce anesthetic agent usage, reducing greenhouse gas emissions and costs, compared to manual control. 1
As healthcare systems continue to face workforce challenges, sicker patients, and increasing costs and administrative demands, the need for efficient care is critical. Automation in anesthesia gas delivery can help reduce manual intervention and cognitive burden for clinicians, while decreasing costs and optimizing patient care.
To ease the way to more efficient care, automated anesthesia gas delivery can also help support low-flow anesthesia —a technique in which anesthetic gas flow is reduced to the lowest level consistent with safe patient care. “In the dynamic surgical environment, the repeated manual adjustment of fresh gas flows and anesthetic vaporizer settings required to deliver low-flow anesthesia can be challenging for anesthesia clinicians. Results from the MASTER trial showed that End-Tidal Control software was able to achieve and sustain desired oxygen and anesthetic agent concentrations more consistently and timely compared to conventional methods,” said Trial Investigator Melinda S. Seering, MD, Clinical Associate Professor of Anesthesia at University of Iowa Healthcare. “As less anesthetic agent is needed to maintain the respective targets, End-tidal Control software can help enhance patient safety in the operating room, while reducing greenhouse gas emissions and costs.”**
The randomized, controlled MASTER trial (Multi-site Anesthesia Randomized Controlled STudy of End Tidal Control Compared to Conventional Anesthesia Results) was conducted across four
Study results showed that the End-tidal Control arm achieved:***
-
Targeted end-tidal anesthetic concentrations within
5% of the set value 98 ±2% of the time, compared to 46 ±32% of the time with manual control (p < 0.0001). -
Targeted end-tidal oxygen concentrations within
5% of the set value 86 ±23% of the time, compared to 41 ±33% of the time with manual control (p < 0.0001). -
Faster response times for achieving
90% of the initial desired end-tidal anesthetic concentration (median 75 seconds), compared to manual control (median 158 seconds) (p=0.0013).
Additionally, results support End-tidal Control’s ability to significantly reduce anesthetic agent usage, reducing greenhouse gas emissions and costs, compared to manual control.**** A separate study also showed a potential
“Anesthesia professionals are focused on patient safety and have a history of utilizing technology to deliver improved clinical outcomes. End-tidal Control enables clinicians to automatically manage adequate oxygen and anesthetic delivery. Clinicians no longer have to continually adjust fresh gas flow and vaporizer settings, freeing up their time to focus on other tasks,” said John Beard, MD, anesthesiologist and Chief Medical Officer of Patient Care Solutions, GE HealthCare. “Results from the MASTER trial reinforce the value of End-tidal Control software in surgical settings to potentially help reduce unnecessary variability in care and meet the unique needs of individual patients.”
GE HealthCare designs anesthesia solutions to support care that can think one step ahead. End-tidal Control software can be used with the Aisys™ CS2 Anesthesia Delivery System to enhance perioperative care. Additionally, the American Medical Association recently approved a new Category III CPT code to help facilities track patient outcomes associated with the use of End-tidal Control software, in addition to its other benefits. For more information, please visit: https://www.gehealthcare.com/products/anesthesia-delivery/aisys-cs2
* End-tidal Control in
** The MASTER trial was funded by GE HealthCare. The views expressed are solely those of Dr. Melinda S. Seering, do not reflect the opinions or beliefs of the University of
*** Median percent deviation from the clinician’s desired end-tidal anesthetic and oxygen targets with End-tidal Control was
**** Studies have shown End-tidal Control can reduce anesthetic agent consumption by over
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a
Follow us on LinkedIn, X , Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
1 McCabe, M., et al. End-Tidal Control Versus Manual Control of Inhalational Anesthesia Delivery: A Randomized Controlled Noninferiority Trial, Anesthesia & Analgesia 2024.
2 Lucangelo, U., Garufi, G., Marras, E. et al. End-tidal versus manually-controlled low-flow anaesthesia. J Clin Monit Comput 28, 117–121 (2014). https://doi.org/10.1007/s10877-013-9516-8. Also refer to the Et Control User’s Reference Manual (5824844-
3 Tay. S, et al. Financial and environmental costs of manual versus automated control of end-tidal gas concentrations, Anaesthesia Intensive Care 2013; 41: 95-105.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240820714523/en/
GE HealthCare Media Contact:
Jennifer Purdue
M +1 267 593 9735
jennifer.purdue@gehealthcare.com
Source: GE HealthCare
FAQ
What were the main findings of the MASTER trial for GE HealthCare's (GEHC) End-tidal Control software?
How does GE HealthCare's (GEHC) End-tidal Control software potentially impact costs and environmental factors?
What is the regulatory status of GE HealthCare's (GEHC) End-tidal Control software?
How might GE HealthCare's (GEHC) End-tidal Control software benefit anesthesia clinicians?
